Orexigen Therapeutics Analyst Coverage Initiated with Price Target by BrokerBank Securities, Inc.

NEW YORK, Oct. 23, 2014 /PRNewswire/ -- Obesity is a serious and growing condition with as many as 2 billion people worldwide considered to be overweight. The World Health Organization further estimates that approximately 500 million of those people are categorized as obese. In the United States alone, more than one-third of all adults are considered to be obese, costing the US healthcare system an estimated $150 billion each year.

Orexigen Therapeutics, Inc. OREX is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. The company recently received FDA approval for its leading drug candidate Contrave in September 2014. Orexigen has a collaboration agreement with Japan's Takeda Pharmaceuticals to develop and commercialize Contrave in the United States, Canada and Mexico.

For more information on OREX and their Contrave weight-loss pill, including valuation, price target, and analyst recommendation, follow the link here at no cost:

http://bit.ly/-OREX-AnalystReport

Copy and paste to browser may be required.

Forward-Looking Disclaimer   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

Not Financial Advice

BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

Compliance Procedure   

Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the analyst report.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/orexigen-therapeutics-analyst-coverage-initiated-with-price-target-by-brokerbank-securities-inc-960555889.html

SOURCE BrokerBank Securities, Inc.